Phathom at jefferies global healthcare conference: growth meets access hurdles
Phathom Pharmaceuticals (PHAT) recently discussed its growth story for VOQUEZNA, an acid-suppression drug for gastroesophageal reflux disease, at the Jefferies Global Healthcare Conference. The company highlighted strong commercial momentum and a potential second growth engine in new indications, even though its shares traded lower and remained near the bottom of their 52-week range.
VOQUEZNA generated $55 million in 2024, $175 million in 2025, and is projected to reach $310 million to $325 million in 2026, with management aiming for 20% to 30% of a 20 million-script market, potentially reaching $1 billion in gastroenterology sales. However, prior authorization and physician workflow remain major hurdles for faster growth.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.